Drug Discovery Today

NOVEMBER 3, 2022

Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumours in 3D models. The University of Bristol-led advance, published in Biofabrication, would allow clinicians to treat the models, known as spheroids, with chemotherapy drugs and radiation to help them understand an individual patient’s resistance to therapies.

Therapies 113

Therapies Drugs 113

Drug Channels

NOVEMBER 1, 2022

Open enrollment is under way for the 2023 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design. For 2023: 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 52% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.

Pharmacy 85

Pharmacy Independent Pharmacies Drugs 85

Drug Patent Watch

NOVEMBER 1, 2022

This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 73

Pharmaceutical Companies Pharmaceuticals Drugs 73

DrugBank

NOVEMBER 3, 2022

This blog is part of a bigger series. Missed part one? Check out the blog post here or Download Your Guide to Quality Drug Data to get the whats, whys, and hows of quality drug data, according to our experts. Quality data will never be the result of a single metric or of executing on one dimension of quality perfectly. Rather, it is the sum of many crucial elements working together.

International 52

International Drugs Science Pharmaceuticals 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Discovery Today

NOVEMBER 2, 2022

BOSTON, Mass. and Oxford, UK – November 2, 2022 – ROME Therapeutics and Enara Bio, two leading biotechnology companies focused on developing novel medicines driven by insights to the dark genome, today announced that they will host the inaugural Dark Genome Symposium on Monday, November 7, 2022 at ROME’s headquarters in Boston. This one-day event brings together leaders from academia, biotech and pharma working on the dark genome to share knowledge, opportunities, applications and challenges to

Research 100

Research 100

Drug Channels

NOVEMBER 4, 2022

Today’s guest post comes from Matthew Balogh, Head of Digital Marketing at Melinta Therapeutics. Matt discusses the ongoing global problem of antimicrobial resistance (AMR). He suggests that lessons learned from the COVID-19 pandemic can inform both innovation in AMR therapies and our understanding of AMR. To learn more about the global challenge of AMR and brainstorm solutions, request an invitation to Innovate4Outcomes ®.

Therapies 84

Therapies Marketing Drugs 84

Conversations in Drug Development Trends

NOVEMBER 3, 2022

BioPharma Dive interviewed our Derek Ansel on how to conduct psychedelic clinical research. In April 2022, the Food and Drug Administration (FDA) issued draft guidance on developing a “Race and Ethnicity Diversity Plan” for clinical trials. This plan, designed to help make clinical trial enrollment more representative, stands to support diversity, equity and inclusion (DEI) initiatives in R&D — a sector that certainly needs more attention across all clinical trials.

Disease 52

Disease Clinical Trials Trials International 52

Drug Discovery Today

NOVEMBER 3, 2022

University of Bath spin-out hailed for revolutionary development to provide world’s first curative therapy for heart failure

Therapies 113

Therapies 113

Antidote

NOVEMBER 2, 2022

We’re thrilled to share that today, we announced an important collaboration with Beyond Celiac, the leading celiac disease organization working to drive diagnosis, advance research, and accelerate the discovery of new treatments and a cure. We’ve been working with this incredible organization to make our celiac disease clinical trial search even better for patients and caregivers — and we’re now unveiling this blend of our matching technology with Beyond Celiac’s deep understanding of the condit

Research 52

Research Clinical Trials Trials Disease 52

Drug Patent Watch

NOVEMBER 4, 2022

Annual Drug Patent Expirations for SLYND Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are nine patents protecting this drug. SLYND drug…. The post New patent for Exeltis Usa drug SLYND appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

PPD

NOVEMBER 1, 2022

Implementing functional service provider (FSP) partnerships is complex and requires significant resources and investments from each stakeholder in the early stages of a relationship. Partnerships involving a high volume of dedicated resources are complicated and time-intensive, requiring significant collaboration across multiple functions. To better manage these complexities, PPD created the implementation lead role to streamline the resource capacity management process and create efficiencies d

Clinical Research 52

Clinical Research International Clinical Trials Research 52

Reprocell

NOVEMBER 1, 2022

Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls. An article published in the Financial Times described how scientists are moving away from animal experimentation toward alternatives that more closely resemble human physiology. 1 The piece, titled "How science is getting closer to a world without ani

Animal Testing 52

Animal Testing Pharma Companies Laboratories Drug Development 52

Antidote

OCTOBER 31, 2022

Clinical trial patient recruitment companies implement a range of methods, from digital advertising to community partnerships, to reach patients that might be a good fit for a study — but because there are many options for companies to work with, it is important that sites and sponsors thoroughly evaluate their options and choose the right vendor for their needs.

Clinical Trials 52

Clinical Trials Trials 52

Drug Patent Watch

NOVEMBER 4, 2022

Annual Drug Patent Expirations for KATERZIA Katerzia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are six patents protecting…. The post New patent for Azurity drug KATERZIA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

ProRelix Research

OCTOBER 31, 2022

A clinical trial is a culmination of the several stages of a drug or medical device development program that begins with the discovery of a candidate molecule followed by preclinical […]. The post IND Data Requirements and US FDA Submission Process appeared first on ProRelix Research.

FDA 52

FDA Clinical Trials Trials Research 52

LifeSciVC

NOVEMBER 1, 2022

By Robert Clarke, CEO and founder of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has been a hallmark year for Kinaset Therapeutics as we’ve continued to advance our P1b trial with our lead asset. We’ve also nearly doubled the size of the team…to 5 employees from 3. A testament to our team, we’ve received a fair amount of praise (and sometimes incredulity) from investors and business development colleagues alike with regard to the amount of progress we have ma

Drug Development 40

Drug Development Trials Marketing Drugs 40

Drug & Device Law

NOVEMBER 2, 2022

Like most judicial clerks (and, for that matter, judges) we found writing dissents more fun than writing majority opinions. Dissents free one from the need to articulate a consensus. Moreover, since a dissent does not establish a precedent that others must at least pretend to follow, the dissent’s author can be less precise and can let the rhetorical fireworks fly.

Government 52

Government Science Trials Research 52

Drug Patent Watch

NOVEMBER 4, 2022

Annual Drug Patent Expirations for DROSPIRENONE Drospirenone is a drug marketed by Exeltis Usa Inc, Barr, Glenmark Pharms Ltd, Hetero Labs Ltd, Hlthcare, Jubilant Cadista, Mylan Labs Ltd, Watson Labs,…. The post New patent for Exeltis Usa drug DROSPIRENONE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

NOVEMBER 3, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Lithuania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

NOVEMBER 3, 2022

Annual Drug Patent Expirations for TRINTELLIX Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from three suppliers. There are ten…. The post New patent for Takeda Pharms drug TRINTELLIX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 3, 2022

Annual Drug Patent Expirations for YUPELRI Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one NDA. It is available from one supplier. There are sixteen…. The post New patent for Mylan Ireland drug YUPELRI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 3, 2022

Annual Drug Patent Expirations for CERDELGA Cerdelga is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Genzyme Corp drug CERDELGA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 3, 2022

Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. There are six patents protecting this drug. This drug has twenty-eight…. The post New patent for Strongbridge drug RECORLEV appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 2, 2022

This chart shows the pharmaceutical companies with patents in the most countries. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the greatest global patent coverage? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

NOVEMBER 1, 2022

Annual Drug Patent Expirations for OSPHENA Osphena is a drug marketed by Duchesnay and is included in one NDA. It is available from one supplier. There are eight patents protecting…. The post New patent expiration for Duchesnay drug OSPHENA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 31, 2022

This chart shows the pharmaceutical companies with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Malaysia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

OCTOBER 31, 2022

Annual Drug Patent Expirations for OXBRYTA Oxbryta is a drug marketed by Global Blood Theraps and is included in two NDAs. There are nine patents protecting this drug. This drug…. The post New patent for Global Blood drug OXBRYTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 29, 2022

This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

NOVEMBER 4, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 4, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 3, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 3, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

NOVEMBER 2, 2022

OSPHENA (ospemifene) Duchesnay Patent: 9,566,252 Expiration: Nov 2, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit…. The post Drug Patent Expirations for the Week of October 30, 2022 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Pharmaceuticals 40